chrX-77683458-T-C

Variant summary

Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2

The NM_000489.6(ATRX):​c.1798A>G​(p.Ile600Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000232 in 1,208,699 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 6 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.000080 ( 0 hom., 0 hem., cov: 22)
Exomes 𝑓: 0.000017 ( 0 hom. 6 hem. )

Consequence

ATRX
NM_000489.6 missense

Scores

2
13

Clinical Significance

Likely benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -0.663

Publications

1 publications found
Variant links:
Genes affected
ATRX (HGNC:886): (ATRX chromatin remodeler) The protein encoded by this gene contains an ATPase/helicase domain, and thus it belongs to the SWI/SNF family of chromatin remodeling proteins. This protein is found to undergo cell cycle-dependent phosphorylation, which regulates its nuclear matrix and chromatin association, and suggests its involvement in the gene regulation at interphase and chromosomal segregation in mitosis. Mutations in this gene are associated with X-linked syndromes exhibiting cognitive disabilities as well as alpha-thalassemia (ATRX) syndrome. These mutations have been shown to cause diverse changes in the pattern of DNA methylation, which may provide a link between chromatin remodeling, DNA methylation, and gene expression in developmental processes. Multiple alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2017]
ATRX Gene-Disease associations (from GenCC):
  • alpha thalassemia-X-linked intellectual disability syndrome
    Inheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics
  • ATR-X-related syndrome
    Inheritance: XL Classification: DEFINITIVE Submitted by: ClinGen
  • intellectual disability-hypotonic facies syndrome, X-linked, 1
    Inheritance: XL Classification: MODERATE Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -16 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.018885225).
BP6
Variant X-77683458-T-C is Benign according to our data. Variant chrX-77683458-T-C is described in ClinVar as Likely_benign. ClinVar VariationId is 581151.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High Hemizygotes in GnomAdExome4 at 6 XL gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ATRXNM_000489.6 linkc.1798A>G p.Ile600Val missense_variant Exon 9 of 35 ENST00000373344.11 NP_000480.3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ATRXENST00000373344.11 linkc.1798A>G p.Ile600Val missense_variant Exon 9 of 35 1 NM_000489.6 ENSP00000362441.4 P46100-1

Frequencies

GnomAD3 genomes
AF:
0.0000803
AC:
9
AN:
112028
Hom.:
0
Cov.:
22
show subpopulations
Gnomad AFR
AF:
0.000259
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000949
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.0000546
AC:
10
AN:
183015
AF XY:
0.00
show subpopulations
Gnomad AFR exome
AF:
0.000459
Gnomad AMR exome
AF:
0.000146
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000173
AC:
19
AN:
1096620
Hom.:
0
Cov.:
32
AF XY:
0.0000166
AC XY:
6
AN XY:
362064
show subpopulations
African (AFR)
AF:
0.000303
AC:
8
AN:
26360
American (AMR)
AF:
0.000170
AC:
6
AN:
35206
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
19370
East Asian (EAS)
AF:
0.0000994
AC:
3
AN:
30189
South Asian (SAS)
AF:
0.00
AC:
0
AN:
54101
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
40530
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4130
European-Non Finnish (NFE)
AF:
0.00000238
AC:
2
AN:
840687
Other (OTH)
AF:
0.00
AC:
0
AN:
46047
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.490
Heterozygous variant carriers
0
1
3
4
6
7
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000803
AC:
9
AN:
112079
Hom.:
0
Cov.:
22
AF XY:
0.00
AC XY:
0
AN XY:
34283
show subpopulations
African (AFR)
AF:
0.000259
AC:
8
AN:
30929
American (AMR)
AF:
0.0000948
AC:
1
AN:
10550
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
2647
East Asian (EAS)
AF:
0.00
AC:
0
AN:
3580
South Asian (SAS)
AF:
0.00
AC:
0
AN:
2683
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
6129
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
217
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
53123
Other (OTH)
AF:
0.00
AC:
0
AN:
1537
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.531
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000214
Hom.:
0
Bravo
AF:
0.0000793
ESP6500AA
AF:
0.000261
AC:
1
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.0000330
AC:
4

ClinVar

Significance: Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:1
Nov 09, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: ATRX c.1798A>G (p.Ile600Val) results in a conservative amino acid change in the encoded protein sequence. Four of four in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.3e-05 in 1208699 control chromosomes including six hemizygotes. To our knowledge, no occurrence of c.1798A>G in individuals affected with ATR-X Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as likely benign. -

Inborn genetic diseases Benign:1
Nov 12, 2021
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Alpha thalassemia-X-linked intellectual disability syndrome Benign:1
Oct 24, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:1
Jun 29, 2020
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes splice predictors and evolutionary conservation, suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function -

ATRX-related disorder Benign:1
Mar 14, 2024
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.056
BayesDel_addAF
Benign
-0.56
T
BayesDel_noAF
Benign
-0.70
CADD
Benign
0.13
DANN
Benign
0.51
FATHMM_MKL
Benign
0.0050
N
LIST_S2
Benign
0.57
T;.
M_CAP
Uncertain
0.11
D
MetaRNN
Benign
0.019
T;T
MetaSVM
Benign
-0.80
T
PhyloP100
-0.66
PrimateAI
Benign
0.26
T
PROVEAN
Benign
0.18
N;N
REVEL
Uncertain
0.30
Sift
Benign
0.94
T;T
Sift4G
Benign
1.0
T;T
Vest4
0.049
MVP
0.36
MPC
0.023
ClinPred
0.011
T
GERP RS
-7.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
gMVP
0.069
Mutation Taster
=95/5
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs375129029; hg19: chrX-76938950; API